Home/ Stocks/ ZBIO

Zenas BioPharma, Inc. Common Stock

ZBIO XNAS

$19.64 +0.43 (+2.23%) ▲ 15-min delayed

Open

$19.27

High

$20.00

Low

$19.01

Volume

289.1K

Market Cap

$1.22B

About Zenas BioPharma, Inc. Common Stock

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 167 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-51,499,000	$-1.22
Q2 2025	$0	$-52,223,000	$-1.25
Q1 2025	$10.00M	$-33,573,000	$-0.80
FY 2024	$5.00M	$-156,988,000	$-11.89

Related Market News

No specific coverage for ZBIO yet. Check out our latest market news or earnings calendar.

Get ZBIO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Zenas BioPharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.